The global atherosclerosis drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of cardiovascular diseases and rising awareness about the risk factors for atherosclerosis. The increase in demand for these drugs is also due to their effectiveness in reducing the risk of cardiovascular diseases and improving quality of life.
The global atherosclerosis drugs market by type includes corticosteroids, PDE4 inhibitors, biologics, skin barrier emollients, CNI immunosuppressants and other types such as cholesterol-lowering agents and statins. Corticosteroids are used for treating inflammation or autoimmune disorders such as rheumatoid arthritis or psoriasis; PDE4 inhibitors are used for treating pulmonary hypertension; biologics are used for treating various inflammatory conditions such as Crohn's disease or ulcerative colitis; skin barrier emollients are used for preventing dryness and cracking on skin caused by external factors like cold weather or windburns; CNI immunosuppressants are used in organ transplantation patients who have been given an organ from a donor with a different blood type than theirs; cholesterol-lowering agents include statins which reduce levels of low-density lipoprotein (LDL) cholesterol in blood while other types include beta blockers which lower high blood pressure by blocking beta receptors that cause constriction of arteries.
North America dominates the global atherosclerosis drugs market with over 40% share followed by Europe with over 30%. Asia Pacific has seen significant growth owing to its large population base coupled with increasing awareness about cardiovascular diseases among people living there.
Some Of The Growth Factors Of This Market:
- The increasing prevalence of cardiovascular diseases is a major factor driving the growth of atherosclerosis drugs market.
- The growing awareness about the risk factors for atherosclerosis and its complications is also expected to fuel the growth of this market in the near future.
- The increasing number of people suffering from diabetes, obesity, and hypertension are also expected to drive this market in coming years.
- Increasing geriatric population base will also be a key driver for this market in coming years as they are more prone to cardiovascular diseases than any other age group.
- Increasing research and development activities by pharmaceutical companies will also be a key driver for this market.
Industry Growth Insights published a new data on “Atherosclerosis Drugs Market”. The research report is titled “Atherosclerosis Drugs Market research by Types (Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others, Atherosclerosis Drug), By Applications (Hospital, Clinic, Retail Pharmacies, Other), By Players/Companies GlaxoSmithKline, Sanofi, F. Hoffmann-L a Roche, Bayer, Novartis, Merck, Janssen Pharmaceutical, Amgen, Pfizer, Atherosclerosis Drug”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Atherosclerosis Drugs Market Research Report
By Type
Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others, Atherosclerosis Drug
By Application
Hospital, Clinic, Retail Pharmacies, Other
By Companies
GlaxoSmithKline, Sanofi, F. Hoffmann-L a Roche, Bayer, Novartis, Merck, Janssen Pharmaceutical, Amgen, Pfizer, Atherosclerosis Drug
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Atherosclerosis Drugs Market Report Segments:
The global Atherosclerosis Drugs market is segmented on the basis of:
Types
Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others, Atherosclerosis Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Retail Pharmacies, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Sanofi
- F. Hoffmann-L a Roche
- Bayer
- Novartis
- Merck
- Janssen Pharmaceutical
- Amgen
- Pfizer
- Atherosclerosis Drug
Highlights of The Atherosclerosis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Corticosteroids
- PDE4 Inhibitors
- Biologics
- Skin Barrier Emollients
- CNI Immunosuppressants
- Others
- Atherosclerosis Drug
- By Application:
- Hospital
- Clinic
- Retail Pharmacies
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Atherosclerosis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Atherosclerosis drugs are medications used to treat atherosclerosis, a condition in which the fatty substances that line the inside of arteries harden and narrow over time. These medications can help reduce the risk of heart attack and stroke.
Some of the key players operating in the atherosclerosis drugs market are GlaxoSmithKline, Sanofi, F. Hoffmann-L a Roche, Bayer, Novartis, Merck, Janssen Pharmaceutical, Amgen, Pfizer, Atherosclerosis Drug.
The atherosclerosis drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Atherosclerosis Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Atherosclerosis Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Atherosclerosis Drugs Market - Supply Chain
4.5. Global Atherosclerosis Drugs Market Forecast
4.5.1. Atherosclerosis Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Atherosclerosis Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Atherosclerosis Drugs Market Absolute $ Opportunity
5. Global Atherosclerosis Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Atherosclerosis Drugs Market Size and Volume Forecast by Type
5.3.1. Corticosteroids
5.3.2. PDE4 Inhibitors
5.3.3. Biologics
5.3.4. Skin Barrier Emollients
5.3.5. CNI Immunosuppressants
5.3.6. Others
5.3.7. Atherosclerosis Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Atherosclerosis Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Atherosclerosis Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Retail Pharmacies
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Atherosclerosis Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Atherosclerosis Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Atherosclerosis Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Atherosclerosis Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Atherosclerosis Drugs Demand Share Forecast, 2019-2026
9. North America Atherosclerosis Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Atherosclerosis Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Atherosclerosis Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Retail Pharmacies
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Atherosclerosis Drugs Market Size and Volume Forecast by Type
9.7.1. Corticosteroids
9.7.2. PDE4 Inhibitors
9.7.3. Biologics
9.7.4. Skin Barrier Emollients
9.7.5. CNI Immunosuppressants
9.7.6. Others
9.7.7. Atherosclerosis Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Atherosclerosis Drugs Demand Share Forecast, 2019-2026
10. Latin America Atherosclerosis Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Atherosclerosis Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Atherosclerosis Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Retail Pharmacies
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Atherosclerosis Drugs Market Size and Volume Forecast by Type
10.7.1. Corticosteroids
10.7.2. PDE4 Inhibitors
10.7.3. Biologics
10.7.4. Skin Barrier Emollients
10.7.5. CNI Immunosuppressants
10.7.6. Others
10.7.7. Atherosclerosis Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Atherosclerosis Drugs Demand Share Forecast, 2019-2026
11. Europe Atherosclerosis Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Atherosclerosis Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Atherosclerosis Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Retail Pharmacies
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Atherosclerosis Drugs Market Size and Volume Forecast by Type
11.7.1. Corticosteroids
11.7.2. PDE4 Inhibitors
11.7.3. Biologics
11.7.4. Skin Barrier Emollients
11.7.5. CNIImmunosuppressants
11.7.6. Others
11.7.7. Atherosclerosis Drug
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Atherosclerosis Drugs Demand Share, 2019-2026
12. Asia Pacific Atherosclerosis Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Atherosclerosis Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Atherosclerosis Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Retail Pharmacies
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Atherosclerosis Drugs Market Size and Volume Forecast by Type
12.7.1. Corticosteroids
12.7.2. PDE4 Inhibitors
12.7.3. Biologics
12.7.4. Skin Barrier Emollients
12.7.5. CNI Immunosuppressants
12.7.6. Others
12.7.7. Atherosclerosis Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Atherosclerosis Drugs Demand Share, 2019-2026
13. Middle East & Africa Atherosclerosis Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Atherosclerosis Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Atherosclerosis Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Retail Pharmacies
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Atherosclerosis Drugs Market Size and Volume Forecast by Type
13.7.1. Corticosteroids
13.7.2. PDE4 Inhibitors
13.7.3. Biologics
13.7.4. Skin Barrier Emollients
13.7.5. CNI Immunosuppressants
13.7.6. Others
13.7.7. Atherosclerosis Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Atherosclerosis Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Atherosclerosis Drugs Market: Market Share Analysis
14.2. Atherosclerosis Drugs Distributors and Customers
14.3. Atherosclerosis Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. F. Hoffmann-L a Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bayer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Merck
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Janssen Pharmaceutical
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Amgen
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pfizer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Atherosclerosis Drug
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
